|
|
Baseline
|
Change 0-12 wk
|
Pa
|
Change 0-24 wk
|
Pb
|
| Insulin, fasting, mU/L |
Goserelin |
8.1 [3.3, 27] |
+1.6 [-1.3, 4.5]cd |
.105 |
+0.2 [-2.3, 2.8] |
.963 |
| |
Bicalutamide |
5.6 [1.9, 16.9] |
-0.6 [-1.6, 0.3] |
|
-0.1 [-1.4, 0.1] |
|
| |
Control |
6.2 [3.3, 16.0] |
-0.6 [-1.8, 1.0] |
|
-0.7 [-2.8, 2.7] |
|
| Glucose, fasting, mmol/L |
Goserelin |
6.0 ± 1.4 |
-0.4 ± 0.2 |
.601 |
-0.3 ± 0.2 |
.960 |
| |
Bicalutamide |
5.8 ± 1.2 |
-0.5 ± 0.3 |
|
-0.6 ± 0.4 |
|
| |
Control |
5.9 ± 1.1 |
-0.1 ± 0.2 |
|
-0.5 ± 0.2 |
|
| Insulin, 2 h postprandial, mU/L |
Goserelin |
43.5 [9.3, 283.7] |
-0.3 [-7.9, 15.9] |
.888 |
+7.7 [-12.5, 37.1] |
.611 |
| |
Bicalutamide |
37.2 [1.6, 144.9] |
+0.3 [-22.5, 17.6] |
|
-7.2 [-33.5, 16.9] |
|
| |
Control |
26.6 [4.5, 91.9] |
-4.4 [-12.7, 8.1] |
|
-2.3 [-14.6, -2.3] |
|
| Total cholesterol, mmol/L |
Goserelin |
5.2 ± 1.4 |
+0.16 ± 0.14 |
.967 |
-0.21 ± 0.14 |
.126 |
| |
Bicalutamide |
5.9 ± 1.4 |
+0.14 ± 0.16 |
|
-0.16 ± 0.18 |
|
| |
Control |
5.8 ± 1.0 |
+0.19 ± 0.10 |
|
+0.20 ± 0.14 |
|
| HDL cholesterol, mmol/L |
Goserelin |
1.47 ± 0.48 |
+0.07 ± 0.06c |
.116 |
+0.08 ± 0.06 |
.635 |
| |
Bicalutamide |
1.55 ± 0.43 |
+0.23 ± 0.05 |
|
+0.16 ± 0.09 |
|
| |
Control |
1.41 ± 0.33 |
+0.17 ± 0.05 |
|
+0.16 ± 0.05 |
|
| Total testosterone, nmol/L |
Goserelin |
16.0 ± 6.9 |
-14.0 ± 1.4cd |
<.001 |
-12.6 ± 1.7cd |
<.001 |
| |
Bicalutamide |
17.7 ± 4.8 |
+10.9 ± 1.5cd |
|
+9.8 ± 2.2cd |
|
| |
Control |
19.5 ± 5.0 |
-1.3 ± 0.7 |
|
+0.7 ± 1.0 |
|
| Estradiol, nmol/L |
Goserelin |
200.1 ± 55.5 |
-97.9 ± 12.2cd |
<.001 |
-82.2 ± 16.3cd |
<.001 |
| |
Bicalutamide |
173.9 ± 40.7 |
+78.3 ± 17.4cd |
|
+73.7 ± 15.7cd |
|
|
Control
|
193.6 ± 43.2
|
-34.3 ± 13.7
|
|
-17.2 ± 13.2
|
|
|
| Abbreviation: HDL, high-density lipoprotein. |
| a Changes compared from baseline to 3 months. |
| b Changes compared from baseline to 6 months by ANOVA. |
| c P < .05 for comparison with other drugs. |
| d P < .05 for comparison with control. |
|
±
SD); changes from baseline (